A7502
DL-Alanine
≥99% (HPLC)
Synonym(s):
(±)-2-Aminopropionic acid
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
CH3CH(NH2)COOH
CAS Number:
Molecular Weight:
89.09
UNSPSC Code:
12352209
NACRES:
NA.26
PubChem Substance ID:
EC Number:
206-126-4
Beilstein/REAXYS Number:
1720250
MDL number:
Quality Level
assay
≥99% (HPLC)
form
powder
technique(s)
ligand binding assay: suitable
color
white to off-white
mp
289 °C (dec.) (lit.)
solubility
H2O: soluble
application(s)
peptide synthesis
SMILES string
CC(N)C(O)=O
InChI
1S/C3H7NO2/c1-2(4)3(5)6/h2H,4H2,1H3,(H,5,6)
InChI key
QNAYBMKLOCPYGJ-UHFFFAOYSA-N
Application
DL-Alanine, a racemic mixture of D- and L-alanine, is used as a model reagent for development of amino acid racemic resolution techniques. DL-Alanine is used in mixed ligand (chelate) studies with transition metals such as Cu(II), Zn(ll) and Cd(ll).
Still not finding the right product?
Explore all of our products under DL-Alanine
Storage Class
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Tatjana Braun et al.
Proceedings of the National Academy of Sciences of the United States of America, 112(30), 9340-9345 (2015-07-01)
The prokaryotic origins of the actin cytoskeleton have been firmly established, but it has become clear that the bacterial actins form a wide variety of different filaments, different both from each other and from eukaryotic F-actin. We have used electron
Randolph M Baral et al.
Journal of feline medicine and surgery, 17(8), 653-666 (2014-10-10)
In-house analysers are commonplace in small animal practices but cannot be calibrated by the operator; therefore, any bias in the generated plasma analyte values cannot be corrected. Guidelines such as grading of renal disease and published reference intervals (RIs) in
Janine Rohrbach et al.
Antiviral therapy, 19(2), 149-159 (2013-09-17)
We investigated changes in biomarkers of liver disease in HIV-HCV-coinfected individuals during successful combination antiretroviral therapy (cART) compared to changes in biomarker levels during untreated HIV infection and to HIV-monoinfected individuals. Non-invasive biomarkers of liver disease (hyaluronic acid [HYA], aspartate